Genprex, Inc. (NASDAQ:GNPX) Forecasted to Post FY2023 Earnings of ($24.10) Per Share

Genprex, Inc. (NASDAQ:GNPX) – Equities researchers at HC Wainwright issued their FY2023 earnings per share estimates for shares of Genprex in a research note issued to investors on Monday, March 25th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($24.10) for the year. HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Genprex’s current full-year earnings is ($21.85) per share. HC Wainwright also issued estimates for Genprex’s Q4 2023 earnings at ($5.39) EPS, Q1 2024 earnings at ($3.37) EPS, Q2 2024 earnings at ($1.60) EPS, Q3 2024 earnings at ($1.18) EPS, Q4 2024 earnings at ($1.03) EPS and FY2024 earnings at ($5.85) EPS.

Genprex Stock Performance

Shares of GNPX stock opened at $2.98 on Wednesday. The stock’s fifty day moving average price is $5.21 and its two-hundred day moving average price is $9.27. The company has a market cap of $4.44 million, a PE ratio of -0.12 and a beta of -0.57. Genprex has a fifty-two week low of $2.50 and a fifty-two week high of $46.00.

Institutional Investors Weigh In On Genprex

Several hedge funds have recently modified their holdings of GNPX. Armistice Capital LLC acquired a new stake in shares of Genprex during the 1st quarter valued at $1,774,000. AMH Equity Ltd bought a new position in Genprex during the 3rd quarter worth $321,000. Rockefeller Capital Management L.P. bought a new position in Genprex during the 1st quarter worth $136,000. Goldman Sachs Group Inc. raised its position in Genprex by 443.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 121,573 shares of the company’s stock worth $275,000 after purchasing an additional 99,186 shares during the last quarter. Finally, Two Sigma Securities LLC bought a new position in Genprex during the 1st quarter worth $70,000. Institutional investors and hedge funds own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.